Inspiring to be at the first presidential session of #ESMO26 with two P3 trials pushing the boundaries of perioperative cancer treatment in very different ways.
14 浏览 · 0 赞 · 0 转发 · 2 回复
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org- Beth Nally@BethN01
And VOLGA. Looks v likely that we can optimise periop treatment in MIBC by reducing EV exposure. Lower neuropathy rates will be important for cured pts. On treatment QoL looks reassuring. Long term QoL data will be key 🧩 particularly given early impact of cystectomy @tompowles1
- Beth Nally@BethN01
Firstly, mRNA vaccine demonstrating efficacy alongside ICI in adj melanoma. An exciting new era in cancer therapy. Encouraging tolerability, with no obvious signal of additional life-altering toxicity so far. Looking forward to seeing how this translates into RCC in V940-004 💉
来源：Beth Nally · x.com